world cancer report - iarc

is frequent and survival rates are poor
(two-year survival of 20-30% for limited
stage disease) although limited stage
small cell cancer has a cure rate of about
10-15%. Treatment should be considered
since good symptom control can be
attained. Prophylactic cranial irradiation
may reduce the risk of brain metastases,
and has recently been shown in metaanalysis
to prolong survival in limited
small cell cancer.
Although survival for stage I cancers may
reach about 65%, overall survival from lung
cancer is poor (Fig. 5.10). In population-
REFERENCES
1. Ferlay J, Bray F, Parkin DM, Pisani P (2001) Globocan
2000: Cancer Incidence and Mortality Worldwide (IARC
Cancer Bases No. 5), Lyon, IARCPress.
2. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J,
eds (1997) Cancer Incidence in Five Continents, Vol. VII
(IARC Scientific Publication No. 143 and IARC Cancerbase
No. 2), Lyon, IARCPress.
3. IARC (1986) Tobacco Smoking (IARC Monographs on
the Evaluation of the Carcinogenic Risk of Chemicals to
Humans, Vol. 38), Lyon, IARCPress.
4. Hackshaw AK, Law MR, Wald NJ (1997) The accumulated
evidence on lung cancer and environmental tobacco
smoke. BMJ, 315: 980-988.
5. Samet JM (1989) Radon and lung cancer. J Natl Cancer
Inst, 81: 745-757.
6. Lubin JH, Boice JD, Edling C, Hornung RW, Howe G,
Kunz E (1994) Radon and lung cancer risk: a joint analysis
of 11 underground miners studies. In: Public Health
Service, National Institute of Health eds, NIH Publication
No. 94-3644, Washington D.C., US Department of Health
and Human Services.
7. Speizer FE, Samet JM (1994) Air pollution and lung cancer.
In: Samet JM ed., Epidemiology of Lung Cancer (Lung
Biology in Health and Disease, Vol. 74), New York, Marcel
Dekker, 131-150.
8. Smith KR, Liu Y (1994) Indoor air pollution in developing
countries. In: Samet JM ed., Epidemiology of Lung
Cancer (Lung Biology in Health and Disease, Vol. 74), New
York, Marcel Dekker, 151-184.
9. World Cancer Research Fund (1997) Lung. In:
WCRF/AICR ed, Food, Nutrition and the Prevention of
Cancer: a Global Perspective, Washington, DC, World
based series from high-income countries,
the five-year relative survival barely
exceeds 10%. However, survival is better
among patients aged less than 55 at diagnosis
(five-year relative survival in the
order of 15%). There is evidence of a very
modest improvement in survival during the
last 20 years. In developing countries, survival
rates are comparable to those in
industrialized countries.
In the light of poor survival rates, prevention
of lung cancer is a priority. However,
the development of novel therapies
remains important in view of the fact that
Cancer Research Fund/American Institute of Cancer
Research, 130-147.
10. Lam S, Shibuya H (1999) Early diagnosis of lung cancer.
Clin Chest Med, 20: 53-61.
11. Mulshine JL, Henschke CI (2000) Prospects for lungcancer
screening. Lancet, 355: 592-593.
12. Montuenga LM, Mulshine JL (2000) New molecular
strategies for early lung cancer detection. Cancer Invest,
18: 555-563.
13. Wright GS, Gruidl ME (2000) Early detection and prevention
of lung cancer. Curr Opin Oncol, 12 : 143-148.
14. Bunn PA, Jr., Soriano A, Johnson G, Heasley L (2000)
New therapeutic strategies for lung cancer: biology and
molecular biology come of age. Chest, 117: 163S-168S.
15. Bennett WP, Hussain SP, Vahakangas KH, Khan MA,
Shields PG, Harris CC (1999) Molecular epidemiology of
human cancer risk: gene-environment interactions and p53
mutation spectrum in human lung cancer. J Pathol, 187: 8-
18.
16. Minna JD, Sekido Y, Fong KM, Gazdar AF (1997)
Molecular biology of lung cancer. In: DeVita VT, Hellman S,
Rosenberg, SA eds, Cancer: Principles and Practice of
Oncology, Philadelphia, Lippincott-Raven Publishers, 849-
857.
17. Williams C (1998) Lung cancer. In: Morris D, Kearsley J,
Williams C eds, Cancer: a comprehensive clinical guide,
Harwood Academic Publishers, 141-152.
18. Antonia SJ, Sotomayor E (2000) Gene therapy for lung
cancer. Curr Opin Oncol, 12: 138-142.
most patients will die of disease progression
and current treatments can be highly
toxic. Trials of vaccination against tumour
specific antigens such as carcinoembryonic
antigen (CEA) and Fuc-GM1 are
underway [18]. A further strategy under
investigation is that of vaccination with
tumour cells designed to have enhanced
immunogenicity due to the expression of,
for example, cytokine granulocytemacrophage
colony-stimulating factor
(GM-CSF).
WEBSITE
NCI Lung Cancer Homepage:
http://www.cancer.gov/cancer_information/cancer_type/
lung/
Lung cancer
187